NCT05411445

Brief Summary

Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 9, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

August 28, 2024

Status Verified

August 1, 2024

Enrollment Period

3 years

First QC Date

June 1, 2022

Last Update Submit

August 27, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Confirmation and validation of the potential role of blood MV and exosomes as predictors of bypass occlusions

    from 15 to 21 months

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients undergoing elective CABG ( coronary artery bypass graft )

You may qualify if:

  • between the ages of 40 and 80
  • Ejection fraction\> 30%
  • coronary artery bypass surgery
  • informed consent
  • Willingness to carry out the follow-up visits and the assessments required by the protocol

You may not qualify if:

  • emergency intervention
  • changes in liver or kidney function
  • changes in coagulation factors
  • associated interventions (valve replacement, carotid endarterectomy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MCH

Cotignola, Ravenna, 48033, Italy

RECRUITING

Central Study Contacts

Alberto Albertini, MD

CONTACT

Elena Tenti

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2022

First Posted

June 9, 2022

Study Start

June 1, 2022

Primary Completion

June 1, 2025

Study Completion

September 1, 2025

Last Updated

August 28, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations